$ACUT
Accustem Sciences Inc.

2024 Q2 Form 10-Q Financial Statement

#000149315224020584 Filed on May 20, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $235.6K $502.5K $816.8K
YoY Change -34.06% -38.48%
% of Gross Profit
Research & Development $41.75K $23.20K $15.60K
YoY Change 186.42% 48.68% -26.21%
% of Gross Profit
Depreciation & Amortization $907.00 $908.00 $908.00
YoY Change 0.0% 0.0% 34.12%
% of Gross Profit
Operating Expenses $278.2K $526.6K $833.3K
YoY Change -25.36% -36.81% 5.41%
Operating Profit -$278.2K -$526.6K -$833.3K
YoY Change -25.36% -36.81% 5.41%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$278.2K -$526.6K -$833.3K
YoY Change -25.36% -36.81% 5.41%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$278.2K -$526.6K -$833.3K
YoY Change -25.36% -36.81% 5.41%
Net Earnings / Revenue
Basic Earnings Per Share -$0.02 -$0.05 -$0.07
Diluted Earnings Per Share -$0.02 -$0.05 -$0.07
COMMON SHARES
Basic Shares Outstanding 11.35M shares 11.35M shares 11.35M shares
Diluted Shares Outstanding 11.35M shares 11.35M shares 11.35M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.07K $9.370K $180.6K
YoY Change -61.82% -94.81%
Cash & Equivalents $46.07K $9.373K $180.6K
Short-Term Investments
Other Short-Term Assets $91.36K $38.43K
YoY Change
Inventory
Prepaid Expenses $91.36K $38.43K $60.15K
Receivables
Other Receivables
Total Short-Term Assets $137.4K $47.80K $240.8K
YoY Change -69.64% -80.15%
LONG-TERM ASSETS
Property, Plant & Equipment $2.233K $3.140K $6.770K
YoY Change -61.91% -53.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.233K $3.140K $6.770K
YoY Change -61.91% -53.62%
TOTAL ASSETS
Total Short-Term Assets $137.4K $47.80K $240.8K
Total Long-Term Assets $2.233K $3.140K $6.770K
Total Assets $139.7K $50.94K $247.6K
YoY Change -69.54% -79.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $744.7K $649.5K $307.1K
YoY Change 94.55% 111.51%
Accrued Expenses $154.9K $219.6K $723.9K
YoY Change -58.31% -69.67%
Deferred Revenue
YoY Change
Short-Term Debt $81.22K $0.00 $0.00
YoY Change -72.73%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.024M $2.671M $1.194M
YoY Change 71.3% 123.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.024M $2.671M $1.194M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.024M $2.671M $1.194M
YoY Change 71.3% 123.65%
SHAREHOLDERS EQUITY
Retained Earnings -$7.327M -$7.049M -$5.305M
YoY Change 29.05% 32.88%
Common Stock $11.35K $11.35K $11.35K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.884M -$2.620M -$946.7K
YoY Change
Total Liabilities & Shareholders Equity $139.7K $50.94K $247.6K
YoY Change -69.54% -79.42%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$278.2K -$526.6K -$833.3K
YoY Change -25.36% -36.81% 5.41%
Depreciation, Depletion And Amortization $907.00 $908.00 $908.00
YoY Change 0.0% 0.0% 34.12%
Cash From Operating Activities -$209.2K -$237.4K -$446.1K
YoY Change -60.0% -46.79% -219.92%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 245.9K $225.2K -$107.3K
YoY Change -46.88% -310.01% -103.72%
NET CHANGE
Cash From Operating Activities -209.2K -$237.4K -$446.1K
Cash From Investing Activities
Cash From Financing Activities 245.9K $225.2K -$107.3K
Net Change In Cash 36.70K -$12.11K -$553.3K
YoY Change -161.18% -97.81% -117.05%
FREE CASH FLOW
Cash From Operating Activities -$209.2K -$237.4K -$446.1K
Capital Expenditures
Free Cash Flow -$446.1K
YoY Change -222.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
pure
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2024Q1 us-gaap Assets Current
AssetsCurrent
47801 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
129849 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3140 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4048 usd
CY2024Q1 us-gaap Assets
Assets
50941 usd
CY2023Q4 us-gaap Assets
Assets
133897 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
649480 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
578378 usd
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1801908 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1454986 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
219567 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
156434 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
55679 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2670955 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2245477 usd
CY2024Q1 us-gaap Liabilities
Liabilities
2670955 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2245477 usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11346535 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11346535 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
11346 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
11346 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4417187 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4399019 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7048547 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6521945 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2620014 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2111580 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50941 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
133897 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23197 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15602 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
503405 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
817739 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
526602 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
833341 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-526602 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-833341 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-526602 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-833341 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-526602 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-833341 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11346535 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11346535 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11346535 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11346535 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-139550 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26209 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-833341 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-946682 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2111580 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2111580 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18168 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-526602 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2620014 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2620014 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-526602 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-833341 usd
CY2024Q1 us-gaap Depreciation
Depreciation
908 usd
CY2023Q1 us-gaap Depreciation
Depreciation
908 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
18168 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
26209 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-69940 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-108276 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-29603 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
71102 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4759 usd
CY2024Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
66000 usd
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
21004 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
63133 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
206010 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-237351 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-446090 usd
CY2024Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
280922 usd
CY2024Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
55679 usd
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
107253 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
225243 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-107253 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12108 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-553343 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21481 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
733978 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9373 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
180635 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
697 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
702 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7048547 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zGDS5IKGmBC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zc8jdSvRLFb5">Use of Estimates </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 ACUT Accrued Legal Expenses Current
AccruedLegalExpensesCurrent
146594 usd
CY2023Q4 ACUT Accrued Legal Expenses Current
AccruedLegalExpensesCurrent
146594 usd
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
72973 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9840 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
219567 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
156434 usd
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q2 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
30822 usd
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10999 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10999 usd
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7859 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6951 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3140 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4048 usd
CY2024Q1 us-gaap Depreciation
Depreciation
908 usd
CY2023Q1 us-gaap Depreciation
Depreciation
908 usd
CY2024Q1 us-gaap Foreign Currency Translation Adjustment Description
ForeignCurrencyTranslationAdjustmentDescription
converted from EUROS to USD using exchange rate of €1:$1.0675
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
846453 usd
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0 shares
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-526602 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-833341 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-526602 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-833341 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11346535 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11346535 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11346535 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11346535 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1702279 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1757244 shares
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1702279 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1757244 shares
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18168 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26209 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0180 pure
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5343 pure
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
822652 usd

Files In Submission

Name View Source Status
0001493152-24-020584-index-headers.html Edgar Link pending
0001493152-24-020584-index.html Edgar Link pending
0001493152-24-020584.txt Edgar Link pending
0001493152-24-020584-xbrl.zip Edgar Link pending
acut-20240331.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
acut-20240331_lab.xml Edgar Link unprocessable
acut-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
acut-20240331_cal.xml Edgar Link unprocessable
acut-20240331_def.xml Edgar Link unprocessable